Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 22, 2026, by Perrigo Company plc. The filing discloses a strategic change to the Company's reporting segments, effective as of the first quarter of 2026. The Company transitioned from a geographic segment structure to a product category-based structure to better align with its organizational vision and the decision-making of its Chief Operating Decision Maker (CODM).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. Instead, it references Exhibit 99.1, which contains "Unaudited Recast Financial Information" for the three months ended March 30, 2024, through December 31, 2025, recast to reflect the new segment definitions. The filing notes that these changes have no impact on the Company's historical consolidated financial position, results of operations, or cash flows.
Material Changes Versus Prior Period
- Segment Restructuring: The Company moved from geographic reporting to product category reporting. The new segments are:
- Self Care: OTC health and wellness products (pain & sleep, respiratory, digestive, vitamins, supplements, electrolytes).
- Specialty Care: Targeted consumer health products (women's health, skin health, insect repellant).
- Infant Formula: Nutrition products for infants.
- All Other: Combines Oral Care and Other categories (including Dermacosmetics).
- Profitability Measure: The primary measure for evaluating segment profitability changed from segment operating income to segment adjusted operating income.
- Historical Data Recasting: Historical financial data for 2024 and 2025 has been recast to align with the new segments for comparability, though this is not a restatement of previously issued financial statements.
Guidance, Outlook, and Management Commentary
Management states that the new structure enables better alignment of financial disclosures with product offerings and strategic priorities. The Company continues to provide non-GAAP financial measures (e.g., adjusted operating income, adjusted diluted EPS, constant currency net sales) to assist investors in evaluating underlying operating trends by excluding items such as amortization, restructuring charges, and acquisition-related costs. The filing explicitly states that the recast information should be read in conjunction with the Annual Report on Form 10-K for the year ended December 31, 2025, and relevant Quarterly Reports on Form 10-Q.
Important Facts for Investor Verification
- Review Exhibit 99.1 for the specific recast financial metrics for the new reporting segments for fiscal years 2024 and 2025.
- Verify the reconciliation between the new non-GAAP segment measures and the GAAP consolidated financial statements.
- Confirm that the change in segment reporting does not alter the Company's consolidated GAAP results, as stated in the filing.
- Examine the definition of "All Other" to understand the composition of the Oral Care and Dermacosmetics businesses within the new structure.